Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 785? excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785? is a trademark of Sirigen Group Ltd.

The GL-1 antibody can block the mixed lymphocyte reaction in vitro and has been shown to inhibit the priming of cytotoxic T lymphocytes in vivo (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation¹, immunohistochemical staining of acetone-fixed frozen sections^2,6, immunofluorescence microscopy, and in vivo and in vitro blocking of T cell responses^1-6. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 105051-105056).

1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed
11. de Verteuil DA, et al. 2014. J Immunol. 193:1121. PubMed

1. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
2. Sepe JJ, et al. 2022. JACC Basic Transl Sci. 7:915. PubMed
3. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
4. Marangoni F, et al. 2021. Cell. . PubMed
5. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
6. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
7. Lam KC, et al. 2021. Cell. 184:5338. PubMed
8. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
9. Seenappa LM, et al. 2022. NPJ Vaccines. 7:128. PubMed
10. Deets KA, et al. 2021. Elife. 10:. PubMed

B cells and T cells (upregulated upon activation), macrophages, dendritic cells, and astrocytes

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Hathcock KS, et al. 1993. Science 262:905.
3. Freeman GJ, et al. 1993. Science 262:907.
4. Carreno BM, et al. 2002. Annu. Rev. Immunol. 20:29.